Sarepta Therapeutics

Update in progress

SRPT (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on RNA-targeted therapeutics, siRNA platforms, gene therapy, and other genetic approaches for rare diseases. Its Duchenne programs include Exondys 51, Vyondys 53, and Amondys 45 for exon-skipping mutations, and Elevidys, an AAV gene therapy with exon-8/9 deletion contraindications. It also develops SRP-9003 for LGMD2E, SRP-1001 (DUX4 knockdown), and SRP-1003 (DMPK reduction). The company collaborates with Roche, Arrowhead, UWA, Nationwide Children’s, Hansa, and Duke. Founded 1980, based in Cambridge, MA.

Company score

Sentiment: -0.57; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.90; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.69; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.41; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.49; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive